Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Constitutive soxR Mutations Contribute to Multiple-Antibiotic Resistance in Clinical Escherichia coli Isolates

Anastasia Koutsolioutsou, Samuel Peña-Llopis, Bruce Demple
Anastasia Koutsolioutsou
Department of Genetics and Complex Diseases and Division of Biological Sciences, Harvard School of Public Health, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Peña-Llopis
Department of Genetics and Complex Diseases and Division of Biological Sciences, Harvard School of Public Health, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Demple
Department of Genetics and Complex Diseases and Division of Biological Sciences, Harvard School of Public Health, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bdemple@hsph.harvard.edu
DOI: 10.1128/AAC.49.7.2746-2752.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The soxRS regulon of Escherichia coli and Salmonella enterica is induced by redox-cycling compounds or nitric oxide and provides resistance to superoxide-generating agents, macrophage-generated nitric oxide, antibiotics, and organic solvents. We have previously shown that constitutive expression of soxRS can contribute to quinolone resistance in clinically relevant S. enterica. In this work, we have carried out an analysis of the mechanism of constitutive soxS expression and its role in antibiotic resistance in E. coli clinical isolates. We show that constitutive soxS expression in three out of six strains was caused by single point mutations in the soxR gene. The mutant SoxR proteins contributed to the multiple-antibiotic resistance phenotypes of the clinical strains and were sufficient to confer multiple-antibiotic resistance in a fresh genetic background. In the other three clinical isolates, we observed, for the first time, that elevated soxS expression was not due to mutations in soxR. The mechanism of such increased soxS expression remains unclear. The same E. coli clinical isolates harbored polymorphic soxR and soxS DNA sequences, also seen for the first time.

Microbial antibiotic resistance has become a major clinical problem worldwide. Many hospital- and community-acquired infections that were easy to treat with the introduction of antibiotics have now become problematic because the bacteria causing them have developed resistance to the most commonly used antibiotics (5, 39). Understanding the mechanisms that underlie the development of antibiotic resistance will aid in designing strategies to overcome this problem.

Bacteria acquire antibiotic resistance in several different ways, many of them specific to individual antibiotics or classes of antibiotics. Plasmid- or transposon-borne genes confer high-level resistance to specific antibiotics (39) by expressing enzymes that inactivate the antibiotic or alter its target in the cell (e.g., β-lactamases or rRNA methylases, respectively) or antibiotic-specific efflux pumps that eliminate the antibiotic from the cell (e.g., the tetracycline efflux pump). Chromosomal mutations can alter the antibiotic's cellular target to render it insensitive to the antibiotic, as in gyrA or parC mutations encoding quinolone-resistant DNA gyrase subunit A or topoisomerase IV (39). Recognized more recently, regulatory mutations in chromosomal genes confer resistance to multiple, structurally unrelated antibiotics by alleviating the antibiotic burden in the cell through decreased influx combined with increased efflux of diverse drugs. This type of resistance is often called intrinsic antibiotic resistance (30).

In Escherichia coli and Salmonella enterica, one such chromosomally encoded genetic system that confers low-level multiple-antibiotic resistance is the soxRS regulon (3, 14, 28, 29). In this system, the SoxR protein is activated by oxidation (8-10, 12, 20, 25, 33) or nitrosylation (6) to trigger transcription of the soxS gene. Through increased expression, the SoxS protein is the direct activator of genes for resistance to both oxidants and antibiotics (37). SoxS is known to control several genes in S. enterica (36) and 65 to 80 genes in E. coli (26, 35, 42). The micF and acrAB genes are among these SoxS-regulated genes and are the main effectors of soxRS-mediated antibiotic resistance. Increased SoxS expression leads to increased expression of the antisense RNA micF (3, 29), down-regulation of the outer membrane porin OmpF, and a decrease in cell permeability. Increased SoxS expression also induces expression of the acrAB-encoded efflux pump (29, 30, 41) and a concurrent increase in efflux pump activity. This combination of increased efflux pump activity and decreased cell permeability results in soxRS-mediated antibiotic resistance.

In laboratory strains of E. coli and S. enterica, activation of the soxRS regulon with paraquat (PQ) treatment or by expression of constitutive SoxR (SoxRc) proteins increases resistance to ampicillin, nalidixic acid, chloramphenicol, and tetracycline two- to fourfold (3). This moderate, multiple-antibiotic resistance is a hallmark of soxRS-mediated mechanisms.

The soxRS regulon is also connected to antibiotic resistance in clinical strains. We previously showed (24) that constitutive soxS expression contributed significantly to the quinolone resistance of an S. enterica clinical isolate, caused by a soxR mutation that evidently arose during clinical treatment. Also, Oethinger et al. (34) found that 16% of fluoroquinolone-resistant, organic solvent-resistant clinical E. coli isolates exhibited constitutive soxS expression. In a similar vein, Webber and Piddock (40) reported that 28% of fluoroquinolone-resistant clinical and veterinary E. coli isolates exhibited constitutively elevated soxS expression. However, the mechanism of increased soxS expression and its role in antibiotic resistance were not investigated in these two studies.

In the work presented here, we have analyzed the mechanism of constitutive soxS expression and its role in antibiotic resistance in a variety of E. coli clinical isolates. We show that constitutive soxS expression in three of six strains studied was caused by point mutations in the soxR gene. In the other three isolates elevated soxS expression was not due to soxR mutations, and the mechanism of such increased soxS expression remains unclear. The mutant SoxR proteins contributed to the multiple-antibiotic resistance phenotypes of the clinical strains and were sufficient to confer multiple-antibiotic resistance when expressed in a fresh genetic background. We also show that the soxRS region in some of the E. coli clinical isolates is characterized by extensive DNA sequence polymorphisms.

MATERIALS AND METHODS

Bacterial strains and plasmids.The strains and plasmids used in these studies, along with their relevant properties and source descriptions, are listed in Table 1. Bacteria were cultured overnight in Luria-Bertani (LB) broth (27) at 37°C, unless otherwise stated.

View this table:
  • View inline
  • View popup
TABLE 1.

Strains and plasmids

RNA extraction and Northern blotting.Overnight bacterial cultures were diluted 1/100 in fresh LB broth and grown with vigorous shaking (250 rpm) for 90 min at 37°C or for 105 min at 30°C, as indicated. At that point, the cultures were split, and the appropriate samples were treated with 1.3 mM PQ. Shaking at 37°C or 30°C and 250 rpm was continued for another 30 to 40 min, and RNA was harvested from 1.5-ml aliquots of culture using the RNeasy Mini kit from QIAGEN. RNA yield was estimated by measuring absorption at 260 nm and 280 nm. The appropriate amount of RNA was electrophoresed on 1.5% agarose gels containing 2% formaldehyde and 0.07 μg/ml ethidium bromide. The RNA was transferred overnight to a nylon membrane using the TurboBlotter downward transfer system (Schleicher & Schuell). The membranes were hybridized with appropriate 32P-labeled probes, and gene expression was quantified on a phosphorimager (Bio-Rad). Hybridization with a 32P-labeled 16S RNA probe was used to control for loading differences.

Sequencing of the soxRS regions from E. coli clinical isolates.A 1-kb fragment corresponding to the soxRS region was amplified by PCR from the genomic DNA of the E. coli clinical isolates. The forward primer was 5′-GGCGAAGCTTCCGCAGGTGTTTATGC-3′ and the reverse primer was 5′-CGTCGGGGGAAGCTTTCCTGTGTACC-3′ (regions corresponding to, respectively, bp 284 to 298 downstream of soxS in the GenBank deposited sequence and bp 1281 to 1271 downstream of soxR are underlined). The amplified fragments were gel purified, and both strands were sequenced at the High-Throughput Sequencing Facility of the Dana-Farber/Harvard Cancer Center.

Cloning of soxR from E. coli clinical isolates.A 600-bp fragment containing the soxR gene and its promoter was amplified by PCR from the genomic DNA of the E. coli clinical isolates. The forward primer was 5′-GCCGCTCGAGCTGAATAATTTTCTGATGGG-3′ (region corresponding to soxS bp 641 to 660 downstream of soxR is underlined) and contained an XhoI site. The reverse primer was the same one used for sequence analysis and contained a HindIII site. After digestion with these enzymes, the PCR fragments were cloned into vector pCR2.1-TOPO using the TOPO TA cloning kit from Invitrogen. Successful clones were confirmed by restriction digestion analysis. Several clones for each mutant were sequenced to verify that no mutations were introduced by the PCR procedure. The cloned soxR alleles were then subcloned under the control of their own promoters into pACYC177 (New England Biolabs) using restriction enzymes XhoI (New England Biolabs) and HindIII (New England Biolabs). The following plasmids were obtained: pAK-WT, which contains the wild-type soxR allele, and pAK-E3, pAK-E17, pAK-E19, pAK-M1, and pAK-I237, which contain, respectively, the soxR alleles from strains E3, E17, E19, M1, and I237 (Table 1). Subcloning was verified by restriction digestion analysis.

Transcriptional activity of cloned soxR alleles.Plasmids pACYC177, pAK-WT, pAK-E3, pAK-E17, pAK-E19, pAK-M1, and pAK-I237 were introduced into strain EH46 (ΔsoxR soxS::lacZ) (Table 2), and the transcriptional activity of the expressed SoxR proteins was assayed by measuring expression of β-galactosidase directed by the reporter gene. The plasmid-bearing strains were grown overnight in LB broth containing 100 μg/ml ampicillin (LB-amp [100 μg/ml]) at 37°C with shaking (235 rpm). The next day, the cultures were subcultured 1/100 into fresh LB-amp (100 μg/ml) medium, grown for 105 min, and split into two cultures, PQ was added at a final concentration of 250 μM to one of each pair, and shaking (235 rpm) continued at 37°C for another 45 min. The cultures were chilled on ice for 15 min, and β-galactosidase activities were assayed in sodium dodecyl sulfate (SDS)-CHCl3-treated cells as described by Miller (27).

View this table:
  • View inline
  • View popup
TABLE 2.

Sequence analysis of soxRS in E. coli clinical isolatesa

Complementation of a ΔsoxR strain with cloned soxR alleles for increased antibiotic resistance.Plasmids pACYC177, pAK-WT, pAK-E3, pAK-E17, pAK-E19, pAK-M1, and pAK-I237 were introduced into strain TN402 (ΔsoxR soxS+) (Table 1), and their contribution to the antibiotic resistance phenotype of the recipient strain was assayed on antibiotic gradient plates. Overnight cultures of TN402 (ΔsoxR) (Table 1) bearing the appropriate plasmids were grown in LB-amp (100 μg/ml) at 37°C with shaking (235 rpm), and samples were applied to an antibiotic gradient plate. The resistance to the antibiotic was determined by measuring growth along the antibiotic gradient after 12 to 24 h of incubation at 37°C. The antibiotics tested were chloramphenicol up to 30 μg/ml, nalidixic acid up to 15 μg/ml, and ciprofloxacin up to 0.125 μg/ml. Antibiotic gradient plates were prepared as described by Cunningham et al. (4), except that each plate contained 60 ml of solid medium.

Multicopy suppression of antibiotic resistance with wild-type soxR.Clinical isolates E17, M1, and I242 and control laboratory strains GC4468, DJ901, JTG936, and JTG1052 were transformed with plasmid pSXR encoding isopropyl-β-d-thiogalactopyranoside (IPTG)-inducible SoxR (Table 1) or the vector (pSE380). Overnight cultures of the transformed strains grown in LB-amp (100 μg/ml) at 37°C with shaking (235 rpm) were applied to antibiotic gradient plates containing 5 μM IPTG. Resistance was assessed as described in the previous section.

RESULTS

Expression of soxS mRNA in E. coli clinical isolates.We sought to determine the molecular basis of the previously reported constitutive soxS expression in antibiotic-resistant clinical E. coli isolates and its possible role in resistance. Strains E3, E17, and E19 (34) (Table 1) were isolated from blood samples from patients at cancer centers in Europe and the Middle East (34). The strains were all highly fluoroquinolone resistant (MIC of 64 μg/ml, compared to ≤0.25 μg/ml for the wild type [34]) and bore mutations in both gyrA and parC (34). Strain M1 (Table 1) was isolated from a urinary tract infection from a nonneutropenic patient (34). Strain M1 had modest fluoroquinolone resistance (MIC, 4 μg/ml [34]) and a gyrA mutation (30). Strains I236, I237, I242, I243, I244, I246, I248, I251, I253, and I254 (40) (Table 1) were obtained from hospitals in Spain. These strains were reported to have intermediate/high fluoroquinolone resistance, resistance to multiple antibiotics and a gyrA mutation (40). All of the above strains had been reported to exhibit high basal soxS mRNA expression (30, 36), but the mechanism(s) underlying this altered expression was unknown.

We first tested whether the strains retained elevated soxS expression under our experimental conditions. In our hands, compared to the wild-type laboratory strain GC4468, strains E17, E19, M1, I237, I242, and I253 all expressed soxS mRNA at elevated levels during normal (“unstressed”) cell growth (Fig. 1). The absolute levels of basal soxS mRNA expression differed among the different strains. Most of the strains tested retained the ability to up-regulate soxS mRNA upon treatment with PQ (Fig. 1A, B, and C and data not shown). In strain E17, basal expression of soxS mRNA was already maximal, as it was not induced further by PQ treatment (Fig. 1A). In strain E19 (Fig. 1A), the high basal level of soxS mRNA was further elevated ∼2-fold by PQ treatment. In strain M1 (Fig. 1B) the basal soxS expression was elevated but to a lesser extent than in strains E17 and E19. Strains I237, I242, and I253 expressed increased basal amounts of soxS mRNA compared to the laboratory strain GC4468 (Fig. 1C), but the absolute level of expression was low compared to the constitutive expression of strain JTG936 (14) (Table 1). None of the other strains expressed detectably increased amounts of soxS mRNA, in contrast to previous reports. However, most of the I-series strains did exhibit elevated basal soxS expression when cultured in Iso-Sensitest broth (M. Webber and L. J. Piddock, personal communication).

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Expression of soxS mRNA in clinical E. coli isolates. Overnight cultures were diluted 1/100 in fresh LB broth and grown with vigorous shaking (250 rpm) for 105 min at 30°C (A and C) or for 90 min at 37°C (B). At that point, the cultures were split, the appropriate samples were treated with 1.3 mM PQ, and shaking resumed at 250 rpm and 30°C or 37°C as appropriate for another 30 to 40 min. RNA was then harvested for Northern analysis. (A) Expression of soxS mRNA in E. coli strains GC4468 (soxR+), E3, E17, E19, and M1, with or without 1.3 mM paraquat treatment. (B) Basal expression of soxS mRNA in E. coli strains GC4468, JTG936 (soxRc), I236, I237, I242, I243, I244, I246, I248, I251, I253, and I254.

Mutations in the soxRS region of the E. coli clinical isolates.Theoretically, constitutive soxS expression could be due to mutations in the soxR gene that render the protein constitutively active, mutations in the soxS promoter that turn on transcription of the soxS gene constitutively (16), changes in the soxS gene that prolong the half-life of the soxS mRNA (6), or mutations in other genes that regulate the redox status of SoxR (8, 9, 11, 12, 22). To address some of these possibilities, we first sequenced the entire soxRS region of each of the clinical isolates.

Table 2 shows that strains E17, E19, M1, I237, I242, and I253, which exhibited increased soxS expression, all harbored missense mutations in the soxR gene. An in-frame 3-bp deletion (C1130A1131G1132) in strain E17 resulted in deletion of serine-128 (S128) within the cysteine cluster of SoxR. A deletion of two consecutive thymines in strain E19 (T1191T1192) resulted in a −1 frameshift at leucine-148 and a termination three codons later, which truncated SoxR three residues from the C terminus. A G808-to-A transition in M1 changed arginine-20 to histidine within the helix-turn-helix motif of the SoxR DNA binding domain. Strains I237, I242, and I253 all harbored the same two differences in the soxR gene compared to the reference laboratory strain: C862 to G changes threonine-38 to serine, and G969 to C changes glycine-74 to arginine. Both of these alterations lie within the second helix-turn-helix motif proposed to participate in DNA binding (1, 16).

The sequence analysis (Table 2) also showed that strains E3 and I251 harbor the same mutation (G1080 to A) that changes alanine-111 to threonine. However, the basal expression of soxS mRNA was not elevated in these strains (Fig. 1). The soxS-soxR intergenic region in all the strains was identical to that in the wild-type laboratory strain.

Various polymorphisms were observed in the clinical strains, either silent mutations or amino acid changes without an apparent phenotypic effect. Strains I237, I242, and I253 harbored nine additional silent point mutations in soxR and eight in soxS (Table 2). All the changes, missense and silent, were identical among the three strains, which suggested that I237, I242, and I253 may have arisen from the same clone. Strains I243 and I246 also shared a silent G1079-to-A change in soxR and a silent G494-to-A change in soxS. They shared both of these polymorphisms with strain I236, which harbored an additional silent point mutation in soxS: a T341-to-C change. Interestingly, strain E17, which we obtained from a different source than strains I236, I243, and I246, also carried the silent G494-to-A polymorphism in soxS.

Constitutive activity of cloned mutant soxR genes.To confirm that the increased basal soxS mRNA expression of the E. coli clinical isolates was actually due to constitutive SoxR activity, we cloned the mutant genes into expression vectors (see Materials and Methods). These plasmids (the empty vector pACYC177 and pAK-WT, pAK-E3, pAK-E17, pAK-E19, pAK-M1, and pAK-I237) were introduced into strain EH46 (ΔsoxR soxS::lacZ) (Table 1). The in vivo activity of the mutant proteins was assayed by measuring β-galactosidase expression in the presence or absence of 250 μM PQ, a redox-cycling agent and inducer of the soxRS regulon (17). Figure 2 shows that the mutant soxR genes from E. coli clinical isolates E17, E19, and M1 expressed proteins that conferred high-level expression of the soxS::lacZ reporter, even in the absence of an activating signal. In contrast, the soxR gene from strain E3 did not appear to encode a constitutively active form of SoxR. These observations are in agreement with the results in Fig. 1A and B, which show expression of soxS mRNA in the clinical isolates. Unexpectedly, the SoxR protein expressed from pAK-I237 did not confer increased basal β-galactosidase expression in strain EH46, despite the elevated soxS expression in strain I237 (Fig. 1C). Treatment with PQ induced β-galactosidase expression greatly and to the same extent (>20-fold) in strains harboring the wild-type (WT), E3, or I237 soxR genes. Paraquat treatment did not increase significantly the expression of β-galactosidase by the E17 and E19 SoxR proteins, while it slightly increased the β-galactosidase activity induced by the M1 protein (Fig. 2). For all three alleles—E17, E19, and M1—uninduced expression was already almost maximal (Fig. 2). PQ-induced expression was highest with pAK-E17, pAK-E19, and pAK-M1 (Fig. 2), while pAK-E3 and pAK-I237 paralleled the levels seen for wild-type SoxR (pAK-WT) (Fig. 2).

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

Regulation of soxS::lacZ by mutant SoxR proteins. Plasmids pACYC177, pAK-WT, pAK-E3, pAK-E17, pAK-E19, pAK-M1, and pAK-I237 carrying no soxR, wild-type soxR, or mutant alleles of soxR were introduced into strain EH46 (ΔsoxR soxS::lacZ) (Table 1), and the transcriptional activity of the expressed SoxR proteins was assayed by measuring expression of β-galactosidase in the presence or absence of 250 μM PQ. The data shown are the means and standard errors of two determinations.

Antibiotic resistance conferred by cloned mutant soxR genes.If the SoxRc proteins contributed to the increased antibiotic resistance phenotype of the E. coli clinical isolates, introduction of these proteins into a laboratory ΔsoxR strain (TN402) (Table 1) would confer antibiotic resistance. Resistance was assayed on antibiotic gradient plates with chloramphenicol, nalidixic acid, or ciprofloxacin (Fig. 3). For all three antibiotics tested, introduction of the E3 (pAK-E3) and I237 (pAK-I237) mutant alleles gave the same basal antibiotic resistance as provided by the wild-type (pAK-WT) allele. The vectors encoding the constitutively active E17 (pAK-E17), E19 (pAK-E19), and M1 (pAK-M1) SoxR proteins conferred significantly higher basal resistance to all three antibiotics tested. For ciprofloxacin, these three mutant alleles increased the basal antibiotic resistance 12-, 8-, and 10-fold, respectively, much more than soxRS-mediated mechanisms alone usually provide (1, 20, 24). Treatment with PQ increased the antibiotic resistance of strains harboring the WT, E3, and I237 soxR alleles significantly and to the same extent for each antibiotic tested (Fig. 3). PQ treatment did not significantly affect the antibiotic resistance conferred by the E17 protein and only moderately increased the antibiotic resistance conferred by the E19 and M1 proteins. These results agree with the reporter gene data shown in Fig. 2.

FIG. 3.
  • Open in new tab
  • Download powerpoint
FIG. 3.

Antibiotic resistance conferred by mutant soxR genes. Plasmids pACYC177, pAK-WT, pAK-E3, pAK-E17, pAK-E19, pAK-M1, and pAK-I237 encoding no soxR, wild-type soxR, or a mutant allele of soxR were introduced into strain TN402 (ΔsoxR) (Table 2), and their contribution to the antibiotic resistance phenotype of the recipient strain was assayed on antibiotic gradient plates in the presence or absence of 50 μM PQ. (A) Chloramphenicol (CHL), 0 to 30 μg/ml; (B) nalidixic acid (NAL), 0 to 15 μg/ml; (C) ciprofloxacin (CIP), 0 to 0.125 μg/ml. The data shown are the means and standard errors of three determinations.

It is worth noting that, even in the absence of PQ, introduction of the wild-type soxR vector pAK-WT into strain TN402 (ΔsoxR) (Table 1) increased its resistance to chloramphenicol about twofold compared to the vector-only control (Fig. 3A). The pAK-E3 vector had a similar effect, and neither pAK-WT nor pAK-E3 affected basal resistance to nalidixic acid or ciprofloxacin (Fig. 3). The soxR-dependent increase in chloramphenicol resistance might reflect activation of SoxR by this drug; however, such activation has not been reported. Chloramphenicol can activate MarA expression, but it was not tested whether this effect was soxR dependent (15).

Conversely, PQ treatment increased the antibiotic resistance of the vector-only control to ciprofloxacin about twofold (Fig. 3). This effect was specific to ciprofloxacin. PQ has been shown to be a weak activator of marA expression (35). This could account for the increased ciprofloxacin resistance in the absence of SoxR, particularly if ciprofloxacin is more sensitive than nalidixic acid and chloramphenicol to the marRAB-mediated resistance mechanisms.

Multicopy suppression of antibiotic resistance with wild-type soxR.Nonactivated wild-type SoxR competes with mutant activated protein (20), which allowed us to assess the contribution of mutant soxR alleles to the antibiotic resistance profile of the clinical strains. We introduced a multicopy vector with or without wild-type soxR into the clinical strains and assayed the basal antibiotic resistance. The soxR vector pSXR significantly reduced the basal antibiotic resistance of strains E17 and M1 to all the antibiotics tested (Fig. 4). The antibiotic resistance of the laboratory soxR constitutive strains JTG936 and JTG1052 was also diminished by the introduction of pSXR, while GC4468 (soxR+) and DJ901 (ΔsoxRS) were unaffected (Fig. 4). In contrast, the antibiotic resistance of strain I242 was not affected by pSXR (Fig. 4), consistent with the nonconstitutive nature of the soxR allele in this strain. Strain E19 was not included in this experiment because of its high resistance to all the available antibiotics. Strains I237 and I253 were not included because attempts to transform them with pSXR or pSE380 were unsuccessful.

FIG. 4.
  • Open in new tab
  • Download powerpoint
FIG. 4.

Multicopy suppression of antibiotic resistance with wild-type soxR. Clinical isolates E17, M1, and I242, as well as control laboratory strains GC4468 (soxR+), DJ901 (ΔsoxRS), JTG936 (soxRc), and JTG1052 (soxRc), were transformed with the IPTG-inducible plasmid pSXR (Table 1) or the vector alone. The antibiotic resistance of the control and pSXR-containing strains was assayed on antibiotic gradient plates in the presence of 5 μM IPTG. The maximum antibiotic concentrations per plate were as follows: for strain E17, chloramphenicol (CHL) at 1.5 mg/ml, ciprofloxacin (CIP) at 250 μg/ml, and tetracycline (TET) at 750 μg/ml; for strain M1, chloramphenicol at 40 μg/ml, ciprofloxacin at 5 μg/ml, and tetracycline at 19 μg/ml; for strain I242, chloramphenicol at 20 μg/ml, ciprofloxacin at 1 μg/ml, and tetracycline at 300 μg/ml; for strains GC4468, DJ901, JTG936, and JTG1052, chloramphenicol at 20 μg/ml, ciprofloxacin at 0.05 μg/ml, and tetracycline at 15 μg/ml. The data shown are the means and standard deviations of three determinations.

DISCUSSION

Koutsolioutsou et al. (24) showed that a multiple-antibiotic-resistant S. enterica clinical isolate harbored a constitutive mutation in soxR that apparently arose during clinical treatment and contributed to the quinolone resistance profile of the strain. This was the first report of a soxRc mutation in clinically antibiotic-resistant S. enterica and the first to test directly the soxRc contribution to antibiotic resistance in a clinical strain. Previous studies (34, 40) had reported the occurrence of constitutive soxS expression in quinolone-resistant E. coli clinical isolates, but the mechanism of this expression or its contribution to antibiotic resistance had not been studied. As we have noted, an understanding of the mechanism of constitutive soxS expression will be important for establishing and eventually interfering with the contribution of the soxRS regulon to the antibiotic resistance phenotype.

Analysis of antibiotic-resistant strains may also provide information for elucidating the signal transduction pathways for soxRS activation. To date, elevated basal expression of soxS in laboratory strains of E. coli has been attributed to mutations in the soxR gene that render the SoxR protein active in the absence of oxidative stress (14, 21, 31, 38). In principle, constitutive soxS expression could also be due to mutations in the soxS promoter, such as the spacer mutations that have been engineered (19), mutations in other genes that function to maintain SoxR in its reduced and inactive state (22, 31), or an increase in the half-life of the soxS message (8).

In the present work, we focused on investigating the molecular mechanism(s) of elevated soxS expression in clinical E. coli isolates (34, 40). To our surprise, only 6 of the 14 reported strains (34, 40) exhibited elevated basal soxS expression under our experimental conditions. Recent experiments suggest that some of this difference may be due to the bacterial culture conditions (Webber and Piddock, personal communication). In this context, it may be important that Webber and Piddock (40) used Iso-Sensitest broth from Oxoid, which contains menadione, a superoxide-generating agent and potent activator of SoxR, at a final concentration of nearly 6 μM, in the range where soxRS begins to be activated (13). Such observations call into question the use of this medium for testing antibiotic resistance.

The strains that exhibited elevated soxS expression in our hands (E17, E19, M1, I237, I242, and I253) (Table 2) all harbored mutations in the soxR gene that change the amino acid sequence of the SoxR protein. An in-frame 3-bp deletion (C1130A1131G1132) in strain E17 resulted in deletion of serine-128 (S128) within the cysteine cluster of SoxR (Table 2). This cysteine cluster anchors the [2Fe-2S] center of the protein, which is the sensor of oxidative stress and critical for signal transduction and activation of the protein (7, 9, 17, 18). The S128 deletion may thus alter the structure of the Fe-S cluster so as to render SoxR active directly or by way of increased sensitivity to oxidation. A deletion of two consecutive thymines (T1191T1192) in strain E19 (Table 2) resulted in a −1 frameshift at leucine-148 (L148), a stop three codons later, and a truncation of the SoxR C terminus by three residues. Previous studies indicated that C-terminal truncations of the protein result in SoxRc (31, 38). Apparently, the C terminus of the protein is important for keeping the protein in its reduced, inactive state, perhaps via interaction with an enzymatic function (8, 9, 11, 12, 22). A G808-to-A transition in strain M1 changes arginine-20 (R20) to histidine (H), altering the same residue as a soxRc mutation (arginine-20 to cysteine) isolated previously in laboratory E. coli (20, 31). Arginine-20 lies within the helix-turn-helix motif of the proposed DNA binding domain of SoxR, such that changes of this residue could affect activity.

The cloned soxR alleles from strains E17, E19, and M1 activated soxS transcription even in the absence of PQ and conferred elevated resistance to several antibiotics. Multicopy suppression of the mutant SoxR in strains E17 and M1 with wild-type SoxR resulted in a decrease of basal antibiotic resistance in these strains. These results support our hypothesis that the E17, E19, and M1 mutant soxR alleles are constitutively active, responsible for the increased basal soxS expression in the respective strains, and contribute significantly to the antibiotic resistance of the clinical strains.

Strains I237, I242, and I253 all harbor the same two alterations of the soxR gene: C862-to-G and G969-to-C transversion mutations changing threonine-38 (T38) to serine (S) and glycine-74 (G74) to arginine (R), respectively. Both of these mutations lie within the second helix-turn-helix motif of the polypeptide, which is thought to participate in DNA binding as suggested by comparison with other members of the MerR family (1, 2). However, this soxR allele did not confer constitutive soxS expression or antibiotic resistance when placed in laboratory strains, nor was the basal antibiotic resistance of strain I242 suppressed by multicopy wild-type soxR (Fig. 4B). This is the first instance of elevated soxS expression in a clinical strain not linked to a soxRc and suggests another mechanism, such as a defect in the systems (such as the rsx operon and the rseC gene [23]) that maintain SoxR in its reduced and inactive state. However, an effort to complement strain I237 with the wild-type rsxC gene did not reduce its soxS mRNA expression (data not shown). Another possibility is that the eight sequence polymorphisms in the I-strain soxS gene (Table 2) change the stability of its mRNA.

Our analysis shows that constitutive mutations in the soxR gene can be significantly involved in antibiotic resistance in clinical E. coli infections. The observations with I237 and the related strains further indicate that alterations elsewhere in the SoxR regulatory pathway may have analogous clinical effects. It seems likely that many additional instances of soxRS involvement in the development of antibiotic resistance might also exist but go unnoticed because of transient and reversible (rather than constitutive) activation of SoxR. Identification of such cases poses a big experimental challenge but is a worthwhile goal.

ACKNOWLEDGMENTS

We are grateful to Stuart Levy and Laura Piddock for providing the clinical E. coli isolates and for helpful discussions. We thank Bernard Weiss for collaborating in the effort to complement strain I237 with the rsxC gene. We are indebted to members of the Demple laboratory for valuable help and discussions.

This work was supported by a grant from the U.S. National Institutes of Health (CA37831) to B.D. A.K. was partially supported by a scholarship from the “Alexander S. Onassis” Public Benefit Foundation. S.P.-L. was supported by a postdoctoral fellowship from the Valencian Government (Generalitat Valenciana) in Spain.

FOOTNOTES

    • Received 11 January 2005.
    • Returned for modification 7 February 2005.
    • Accepted 7 March 2005.
  • American Society for Microbiology

REFERENCES

  1. ↵
    Chander, M., and B. Demple. 2004. Functional analysis of SoxR residues affecting transduction of oxidative stress signals into gene expression. J. Biol. Chem. 279:41603-41610.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Changela, A., K. Chen, Y. Xue, J. Holschen, C. E. Outten, T. V. O'Halloran, and A. Mondragon. 2003. Molecular basis of metal-ion selectivity and zeptomolar sensitivity by CueR. Science 301:1383-1387.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Chou, J. H., J. T. Greenberg, and B. Demple. 1993. Posttranscriptional repression of Escherichia coli OmpF protein in response to redox stress: positive control of the micF antisense RNA by the soxRS locus. J. Bacteriol. 175:1026-1031.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Cunningham, R. P., S. M. Saporito, S. G. Spitzer, and B. Weiss. 1986. Endonuclease IV (nfo) mutant of Escherichia coli. J. Bacteriol. 168:1120-1127.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Dennesen, P. J., M. J. Bonten, and R. A. Weinstein. 1998. Multiresistant bacteria as a hospital epidemic problem. Ann. Med. 30:176-185.
    OpenUrlPubMedWeb of Science
  6. ↵
    Ding, H., and B. Demple. 2000. Direct nitric oxide signal transduction via nitrosylation of iron-sulfur centers in the SoxR transcription activator. Proc. Natl. Acad. Sci. USA 97:5146-5150.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Ding, H., and B. Demple. 1996. Glutathione-mediated destabilization in vitro of [2Fe-2S] centers in the SoxR regulatory protein. Proc. Natl. Acad. Sci. USA 93:9449-9453.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Ding, H., and B. Demple. 1997. In vivo kinetics of a redox-regulated transcriptional switch. Proc. Natl. Acad. Sci. USA 94:8445-8449.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Ding, H., E. Hidalgo, and B. Demple. 1996. The redox state of the [2Fe-2S] clusters in SoxR protein regulates its activity as a transcription factor. J. Biol. Chem. 271:33173-33175.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Gaudu, P., N. Moon, and B. Weiss. 1997. Regulation of the soxRS oxidative stress regulon. Reversible oxidation of the Fe-S centers of SoxR in vivo. J. Biol. Chem. 272:5082-5086.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Gaudu, P., and B. Weiss. 2000. Flavodoxin mutants of Escherichia coli K-12. J. Bacteriol. 182:1788-1793.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Gaudu, P., and B. Weiss. 1996. SoxR, a [2Fe-2S] transcription factor, is active only in its oxidized form. Proc. Natl. Acad. Sci. USA 93:10094-10098.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Greenberg, J. T., J. H. Chou, P. A. Monach, and B. Demple. 1991. Activation of oxidative stress genes by mutations at the soxQ/cfxB/marA locus of Escherichia coli. J. Bacteriol. 173:4433-4439.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Greenberg, J. T., P. Monach, J. H. Chou, P. D. Josephy, and B. Demple. 1990. Positive control of a global antioxidant defense regulon activated by superoxide-generating agents in Escherichia coli. Proc. Natl. Acad. Sci. USA 87:6181-6185.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Hächler, H., S. P. Cohen, and S. B. Levy. 1991. marA, a regulated locus which controls expression of chromosomal multiple antibiotic resistance in Escherichia coli. J. Bacteriol. 173:5532-5538.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Heldwein, E. E., and R. G. Brennan. 2001. Crystal structure of the transcription activator BmrR bound to DNA and a drug. Nature 409:378-382.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Hidalgo, E., J. M. Bollinger, Jr., T. M. Bradley, C. T. Walsh, and B. Demple. 1995. Binuclear [2Fe-2S] clusters in the Escherichia coli SoxR protein and role of the metal centers in transcription. J. Biol. Chem. 270:20908-20914.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Hidalgo, E., and B. Demple. 1994. An iron-sulfur center essential for transcriptional activation by the redox-sensing SoxR protein. EMBO J. 13:138-146.
    OpenUrlPubMedWeb of Science
  19. ↵
    Hidalgo, E., and B. Demple. 1997. Spacing of promoter elements regulates the basal expression of the soxS gene and converts SoxR from a transcriptional activator into a repressor. EMBO J. 16:1056-1065.
    OpenUrlAbstract
  20. ↵
    Hidalgo, E., H. Ding, and B. Demple. 1997. Redox signal transduction via iron-sulfur clusters in the SoxR transcription activator. Trends Biochem. Sci. 22:207-210.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Hidalgo, E., H. Ding, and B. Demple. 1997. Redox signal transduction: mutations shifting [2Fe-2S] centers of the SoxR sensor-regulator to the oxidized form. Cell 88:121-129.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Kobayashi, K., and S. Tagawa. 1999. Isolation of reductase for SoxR that governs an oxidative response regulon from Escherichia coli. FEBS Lett. 451:227-230.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Koo, M. S., J. H. Lee, S. Y. Rah, W. S. Yeo, J. W. Lee, K. L. Lee, Y. S. Koh, S. O. Kang, and J. H. Roe. 2003. A reducing system of the superoxide sensor SoxR in Escherichia coli. EMBO J. 22:2614-2622.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Koutsolioutsou, A., E. A. Martins, D. G. White, S. B. Levy, and B. Demple. 2001. A soxRS-constitutive mutation contributing to antibiotic resistance in a clinical isolate of Salmonella enterica (Serovar Typhimurium). Antimicrob. Agents Chemother. 45:38-43.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Liochev, S. I., L. Benov, D. Touati, and I. Fridovich. 1999. Induction of the soxRS regulon of Escherichia coli by superoxide. J. Biol. Chem. 274:9479-9481.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Martin, R. G., and J. L. Rosner. 2002. Genomics of the marA/soxS/rob regulon of Escherichia coli: identification of directly activated promoters by application of molecular genetics and informatics to microarray data. Mol. Microbiol. 44:1611-1624.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Miller, J. H. 1992. A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
  28. ↵
    Miller, P. F., L. F. Gambino, M. C. Sulavik, and S. J. Gracheck. 1994. Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli. Antimicrob. Agents Chemother. 38:1773-1779.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Miller, P. F., and M. C. Sulavik. 1996. Overlaps and parallels in the regulation of intrinsic multiple-antibiotic resistance in Escherichia coli. Mol. Microbiol. 21:441-448.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859.
    OpenUrlFREE Full Text
  31. ↵
    Nunoshiba, T., and B. Demple. 1994. A cluster of constitutive mutations affecting the C-terminus of the redox-sensitive SoxR transcriptional activator. Nucleic Acids Res. 22:2958-2962.
    OpenUrlCrossRefPubMedWeb of Science
  32. Nunoshiba, T., T. DeRojas-Walker, S. R. Tannenbaum, and B. Demple. 1995. Roles of nitric oxide in inducible resistance of Escherichia coli to activated murine macrophages. Infect. Immun. 63:794-798.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Nunoshiba, T., E. Hidalgo, C. F. Amabile Cuevas, and B. Demple. 1992. Two-stage control of an oxidative stress regulon: the Escherichia coli SoxR protein triggers redox-inducible expression of the soxS regulatory gene. J. Bacteriol. 174:6054-6060.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Oethinger, M., I. Podglajen, W. V. Kern, and S. B. Levy. 1998. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob. Agents Chemother. 42:2089-2094.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Pomposiello, P. J., M. H. Bennik, and B. Demple. 2001. Genome-wide transcriptional profiling of the Escherichia coli responses to superoxide stress and sodium salicylate. J. Bacteriol. 183:3890-3902.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Pomposiello, P. J., and B. Demple. 2000. Identification of SoxS-regulated genes in Salmonella enterica serovar Typhimurium. J. Bacteriol. 182:23-29.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Pomposiello, P. J., and B. Demple. 2001. Redox-operated genetic switches: the SoxR and OxyR transcription factors. Trends Biotechnol. 19:109-114.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Tsaneva, I. R., and B. Weiss. 1990. soxR, a locus governing a superoxide response regulon in Escherichia coli K-12. J. Bacteriol. 172:4197-4205.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Walsh, C. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775-781.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Webber, M. A., and L. J. Piddock. 2001. Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of Escherichia coli. Antimicrob. Agents Chemother. 45:1550-1552.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    White, D. G., J. D. Goldman, B. Demple, and S. B. Levy. 1997. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J. Bacteriol. 179:6122-6126.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Zheng, M., X. Wang, L. J. Templeton, D. R. Smulski, R. A. LaRossa, and G. Storz. 2001. DNA microarray-mediated transcriptional profiling of the Escherichia coli response to hydrogen peroxide. J. Bacteriol. 183:4562-4570.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Constitutive soxR Mutations Contribute to Multiple-Antibiotic Resistance in Clinical Escherichia coli Isolates
Anastasia Koutsolioutsou, Samuel Peña-Llopis, Bruce Demple
Antimicrobial Agents and Chemotherapy Jun 2005, 49 (7) 2746-2752; DOI: 10.1128/AAC.49.7.2746-2752.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Constitutive soxR Mutations Contribute to Multiple-Antibiotic Resistance in Clinical Escherichia coli Isolates
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Constitutive soxR Mutations Contribute to Multiple-Antibiotic Resistance in Clinical Escherichia coli Isolates
Anastasia Koutsolioutsou, Samuel Peña-Llopis, Bruce Demple
Antimicrobial Agents and Chemotherapy Jun 2005, 49 (7) 2746-2752; DOI: 10.1128/AAC.49.7.2746-2752.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596